G. Lledo

发表

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

R. Labianca, M. Ducreux, J. Taïeb, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer.

T. Conroy, Y. Bécouarn, O. Bouché, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preoperative Treatment Combining Capecitabine with Radiation Therapy in Rectal Cancer: A GERCOR Phase II Study

C. Hennequin, G. Lledo, O. Dupuis, 2008, Oncology.

Any clinical benefit from the use of oncofoetal markers in the management of chemotherapy for patients with metastatic colorectal carcinomas?

C. Lombard-Bohas, P. Valette, F. Chapuis, 2004, Clinical oncology (Royal College of Radiologists (Great Britain)).

Pharmacogenetic tailoring of irinotecan-based first-line chemotherapy in metastatic colorectal cancer: results of a pilot study.

G. Milano, E. Chatelut, J. Delord, 2011, Anticancer research.

Bevacizumab (Bev) with or without erlotinib as maintenance therapy, following induction first-line chemotherapy plus Bev, in patients (pts) with metastatic colorectal cancer (mCRC): Efficacy and safety results of the International GERCOR DREAM phase III trial.

W. Scheithauer, F. Bonnetain, A. de Gramont, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Late toxicities and clinical outcome at 5 years of the ACCORD 12/0405-PRODIGE 02 trial comparing two neoadjuvant chemoradiotherapy regimens for intermediate-risk rectal cancer

T. Conroy, Y. Bécouarn, O. Bouché, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients.

G. Milano, L. Mineur, M. Etienne-Grimaldi, 2010, British journal of clinical pharmacology.

Postoperative chemoradiotherapy after surgical resection of gastric adenocarcinoma: can LV5FU2 reduce the toxic effects of the MacDonald regimen? A report on 23 patients.

P. Rougier, O. Bouché, J. Seitz, 2005, Gastroenterologie clinique et biologique.

Platinum-sensitivity in metastatic colorectal cancer: towards a definition.

C. Tournigand, F. Bonnetain, A. Larsen, 2013, European journal of cancer.

Capecitabine plus oxaliplatin (XELOX) versus 5‐fluorouracil/leucovorin plus oxaliplatin (FOLFOX‐6) as first‐line treatment for metastatic colorectal cancer

T. Conroy, M. Ychou, M. Ducreux, 2011, International journal of cancer.

Quality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancer

T. Conroy, M. Ychou, M. Ducreux, 2009, British Journal of Cancer.

Efficacy and safety findings from a randomized phase III study of capecitabine (X) + oxaliplatin (O) (XELOX) vs. infusional 5- FU/LV + O (FOLFOX-6) for metastatic colorectal cancer (MCRC)

T. Conroy, M. Ychou, M. Ducreux, 2007 .

Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study.

C. Tournigand, A. Figer, F. Bidard, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients

A. de Gramont, B. Landi, T. André, 2006, British Journal of Cancer.

Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2.

Christophe Hennequin, Bernard Denis, Pierre-Luc Etienne, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cost-Minimisation Analysis in First-Line Treatment of Metastatic Colorectal Cancer in France: XELOX versus FOLFOX-6

T. Conroy, M. Ychou, M. Ducreux, 2011, Oncology.

Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset.

R. Greil, B. Chauffert, S. Barni, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

FOLFOX in patients aged between 76 and 80 years with metastatic colorectal cancer

C. Tournigand, A. Figer, A. de Gramont, 2007, Cancer.

Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study.

P. Hammel, A. de Gramont, C. Bouleuc, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study

C. Tournigand, M. Buyse, A. de Gramont, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant treatment of colon cancer: Xelox considered as commonplace therapy?

G. Lledo, P. Artru, 2012 .

Novel (60%) and recurrent (40%) androgen receptor gene mutations in a series of 59 patients with a 46,XY disorder of sex development.

P. Lapunzina, M. Campo, J. Calaf, 2010, The Journal of clinical endocrinology and metabolism.

OPTIMOX study: FOLFOX 7/LV5FU2 compared to FOLFOX 4 in patients with advanced colorectal cancer.

A. Figer, L. Mineur, A. de Gramont, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Anti-epidermal growth factor receptor therapy in combination with chemoradiotherapy for the treatment of locally advanced anal canal carcinoma: Results of a phase I dose-escalation study with panitumumab (FFCD 0904).

C. Lepage, D. Cowen, X. Mirabel, 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC). A GERCOR study.

L. Mineur, A. de Gramont, A. Gramont, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

5-fluorouracil, folinic acid and oxaliplatin (FOLFOX) in very old patients with metastatic colorectal cancer

I. Chirivella, A. Figer, F. Rivera, 2004 .

Modified (m)Folfox7/bevacizumab (B) or modified (m)Xelox/bevacizumab with or without erlotinib (E) in first-line metastatic colorectal cancer (MCRC): Results of the feasibility phase of the DREAM-OPTIMOX3 study (GERCOR)

C. Tournigand, W. Scheithauer, A. Gramont, 2007 .

Factoring drug-free intervals into the management of patients with advanced colorectal cancer

C. Tournigand, A. Larsen, A. Gramont, 2007 .

497OBEVACIZUMAB-ERLOTINIB AS MAINTENANCE THERAPY IN METASTATIC COLORECTAL CANCER. FINAL RESULTS OF THE GERCOR DREAM STUDY.

C. Tournigand, W. Scheithauer, F. Bonnetain, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Who can benefit from chemotherapy holidays after first-line therapy for advanced colorectal cancer? A GERCOR study

C. Tournigand, A. Figer, A. Larsen, 2008 .

Phase II evaluation of an alternated FOLFOX/FOLFIRI regimen in patients with resistant metastatic colorectal cancer (CRC)

C. Tournigand, M. Hebbar, A. Gramont, 2001 .

Duration of disease control (DDC) or time to failure of strategy (TFS) to evaluate a chemotherapy strategy in advanced colorectal cancer (ACC).

C. Tournigand, F. Bonnetain, A. de Gramont, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

EC3 COST-MINIMIZATION ANALYSIS OF CAPECITABINE + OXALIPLATIN (XELOX) VS. INFUSIONAL 5-FU/LV + OXALIPLATIN (FOLFOX-6) AS FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER (MCRC) IN THE FRENCH SETTING

T. Conroy, M. Ychou, M. Ducreux, 2007 .

Computed tomography scan efficacy in staging gastric linitis plastica lesion: a retrospective multicentric French study

R. Coriat, T. Walter, C. Brézault, 2018, Cancer management and research.

Phase III, randomized, open-label study of capecitabine (X) plus oxaliplatin (XELOX) vs. infusional 5-FU/LV plus oxaliplatin (FOLFOX-6) first-line treatment in patients (pts) with metastatic colorectal cancer (MCRC): Findings from an interim safety analysis

T. Conroy, M. Ychou, M. Ducreux, 2005 .

Carcinoma suprarrenal virilizante en la infancia. Revisión de la bibliografía

G. Lledo, M. Gallego, C. Sarrión, 2005 .

mFOLFOX-bevacizumab or XELOX-bevacizumab then bevacizumab (B) alone or with erlotinib (E) in first-line treatment of patients with metastatic colorectal cancer (mCRC): Interim safety analysis of DREAM study.

C. Tournigand, W. Scheithauer, A. de Gramont, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[Analysis of the medical activity related to cancer in a network of multidisciplinary hospitals using claims databases, the reseau Concorde Oncology Network].

A. Schott, B. Gelas‐Dore, F. Gilly, 2005, Bulletin du cancer.

528PAFLIBERCEPT + FOLFIRI FOR TREATMENT OF METASTATIC COLORECTAL CANCER AFTER OXALIPLATIN FAILURE: 4TH INTERIM SAFETY DATA FROM THE GLOBAL AFLIBERCEPT SAFETY AND QUALITY-OF-LIFE PROGRAM (ASQOP/AFEQT STUDIES).

V. Heinemann, J. Taieb, A. Sobrero, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

FOLFIRI.3, a new regimen combining 5-fluorouracil, folinic acid and irinotecan, for advanced pancreatic cancer: results of an Association des Gastro-Enterologues Oncologues (Gastroenterologist Oncologist Association) multicenter phase II study.

J. Taïeb, J. Spano, J. Taieb, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial.

C. Tournigand, W. Scheithauer, D. Vernerey, 2015, The Lancet. Oncology.

Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors for Which FISH Analysis Does Not Detect an Increase in EGFR Gene Copy Number

A. Italiano, J. Gugenheim, P. Follana, 2008, Annals of Surgical Oncology.

Concomitant administration of weekly oxaliplatin, fluorouracil continuous infusion, and radiotherapy after 2 months of gemcitabine and oxaliplatin induction in patients with locally advanced pancreatic cancer: a Groupe Coordinateur Multidisciplinaire en Oncologie phase II study.

E. Touboul, L. Mineur, J. Balosso, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Concomitant administration of weekly oxaliplatin, 5FU continuous infusion and radiotherapy in locally advanced pancreatic cancer (LAPC): A GERCOR phase II study.

E. Touboul, L. Mineur, J. Balosso, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of aflibercept with FOLFOX and maintenance with fluoropyrimidine as first‑line therapy for metastatic colorectal cancer: GERCOR VELVET phase II study.

C. Tournigand, G. Deplanque, F. Bonnetain, 2019, International journal of oncology.

Phase II trial of weekly alternating sequential BIBF 1120 and afatinib for advanced colorectal cancer.

M. Ducreux, O. Bouché, A. de Gramont, 2011, Anticancer research.

[Definitive treatment of anal canal carcinoma with radiotherapy: adverse impact of a pre-radiation resection. A retrospective study of 57 patients treated with curative intent].

G. Lledo, P. Artru, S. Taieb, 2009, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803.

D. Arsène, P. Rougier, B. Buecher, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study.

C. Tournigand, L. Mineur, A. Larsen, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.

C. Tournigand, M. Buyse, I. Chirivella, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Anti-angiogenic agents in treatment of metastatic colo-rectal cancers

A. Gramont, Hôpital Saint-Antoine, G. Lledo, 2010 .

Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1.

M. Buyse, O. Bouché, A. de Gramont, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer.

C. Tournigand, M. Buyse, I. Chirivella, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II Trial Alternating FOLFOX-6 and FOLFIRI Regimens in Second-Line Therapy of Patients with Metastatic Colorectal Cancer (FIREFOX Study)

C. Tournigand, M. Hebbar, A. de Gramont, 2006, Cancer investigation.

[Adjuvant treatment of colon cancer MOSAIC study's main results].

C. Tournigand, A. de Gramont, T. André, 2006, Bulletin du cancer.

Assessment of tumour response to chemotherapy for metastatic colorectal cancer: accuracy of the RECIST criteria.

C. Lombard-Bohas, O. Pellet, P. Valette, 2002, The British journal of radiology.

Cetuximab efficacy and safety in a retrospective cohort of elderly patients with heavily pretreated metastatic colorectal cancer.

J. Tabernero, F. Lévi, P. Rougier, 2008, Critical reviews in oncology/hematology.

GemOx (Gemcitabine + Oxaliplatin) versus Gem (Gemcitabine) in non resectable pancreatic adenocarcinoma : final results of the GERCOR /GISCAD Intergroup Phase III.

R. Labianca, M. Ducreux, A. Zaniboni, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

5-Fluorouracil, folinic acid and oxaliplatin (FOLFOX) in poor prognosis patients with metastatic colorectal cancer.

C. Tournigand, I. Chirivella, A. Figer, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

FOLFOX in patients with metastatic colorectal cancer and high alkaline phosphatase level: an exploratory cohort of the GERCOR OPTIMOX1 study.

C. Tournigand, M. Buyse, A. Figer, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Surgery of colorectal metastasis in the Optimox 1 study. A GERCOR Study.

B. Gayet, A. Figer, A. de Gramont, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemoradiation with FOLFOX plus cetuximab in locally advanced cardia or esophageal cancer: Final results of a GERCOR phase II trial (ERaFOX).

L. Mineur, F. Di Fioré, A. de Gramont, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[BRAF V600E-mutant colorectal cancers: Where are we?]

A. Lièvre, T. André, E. Samalin, 2020, Bulletin du Cancer.

A phase II trial of weekly alternating sequential administration of BIBF1120 and BIBW2992 in patients with advanced colorectal cancer

M. Ducreux, O. Bouché, A. Gramont, 2008 .

Complete pathological response of unresectable liver metastases from colorectal cancer after trans-arterial chemoembolization with drug-eluting beads loaded with irinotecan (DEBIRI) and concomitant systemic FOLFOX: A case report from the FFCD 1201 trial.

J. Taieb, O. Pellerin, E. Watkin, 2015, Clinics and research in hepatology and gastroenterology.

Chemoradiotherapy with FOLFOX plus cetuximab in locally advanced oesophageal cancer: The GERCOR phase II trial ERaFOX.

F. Bonnetain, L. Mineur, F. Di Fioré, 2016, European journal of cancer.

Improving safety in first-line metastatic colorectal cancer (MCRC) therapy with bevacizumab: Modified FOLFOX7 versus XELOX2—Results of the induction phase of the GERCOR DREAM randomized phase III study.

C. Tournigand, W. Scheithauer, F. Bonnetain, 2015 .

Capecitabine (X) chemoradiation (CRT) in the preoperative treatment of patients (pts) with rectal adenocarcinomas: A phase II GERCOR trial.

C. Hennequin, G. Lledo, O. Dupuis, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

46 Randomized phase II trial of LV5FU2, LV5FU2-cisplatinum or LV5FU2-irinotecan in patients (pts) with metastatic gastric or cardial adenocarcinoma (MGA): final results of study FFCD 9803

D. Arsène, O. Bouché, J. Raoul, 2003 .

Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study.

C. Bouleuc, A. Gramont, C. Louvet, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.

C. Tournigand, A. de Gramont, C. Louvet, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study

C. Tournigand, M. Buyse, A. de Gramont, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Care pathway of patients with metastatic pancreatic cancer in daily practice in France: Results from the REPERE national survey.

F. Bonnetain, P. Hammel, R. Coriat, 2017, Bulletin du cancer.

Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study.

C. Tournigand, F. Bidard, A. Gramont, 2009, Annals of Oncology.

Cost-minimization analysis of a phase III study of capecitabine + oxaliplatin (XELOX) vs. infusional 5-FU/LV + oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer (MCRC) in the French setting

T. Conroy, M. Ychou, M. Ducreux, 2007 .

FOLFOX in patients with metastatic colorectal cancer and high alkaline phosphatase level: an exploratory cohort of the GERCOR OPTIMOX1 study.

C. Tournigand, L. Mineur, A. Gramont, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

V. Heinemann, J. Taieb, A. Sobrero, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Ziv-aflibercept (Z) in combination with FOLFIRI for second-line treatment of patients (pts) with metastatic colorectal cancer (mCRC): Interim safety data from the global aflibercept safety and quality-of-life program in pts pretreated with bevacizumab (B).

D. Ferry, S. Siena, J. Taieb, 2014 .

5-fluorouracil, folinic acid and oxaliplatin (FOLFOX) in very old patients with metastatic colorectal cancer.

I. Chirivella, A. Figer, F. Rivera, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Individual genotyping to optimize chemotherapy in metastatic colorectal cancer (MCRC): The COLOGEN trial

G. Milano, J. Delord, G. Freyer, 2007 .